Drug intelligence / Profile preview

Inolas

Development stage: Unknown
Lead developer: Taiho Pharmaceutical
Administration: Oral

Overview

**Inolas** is a Japanese prescription, semi-digested polymeric enteral nutrition formula developed by EN Otsuka Pharmaceutical for nutritional support in people unable to maintain adequate oral intake, including patients requiring tube feeding. Developed as EN-P05, it is a high-calorie, high-protein liquid formulation providing 1.6 kcal/mL, 6.40 g protein per 100 mL, and essential vitamins and trace elements; it is administered orally or through an enteral feeding tube. It was approved in Japan for nutritional maintenance after surgery, particularly when long-term oral food intake is difficult. ([pmda.go.jp](https://www.pmda.go.jp/drugs/2019/P20190412002/130589000_23100AMX00279_A100_1.pdf))

Brand names: Inolas
Other names: Inolas combination enteral liquidイノラス配合経腸用液

Beyond the preview

Go deeper on Inolas.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Inolas.

Explore the full profile